Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Adrien Monard
Observed name:
A. Monard
Institutions:
Agence Nationale de Sécurité du Médicament et des Produits de Santé,
Groupe Hospitalier Mutualiste de Grenoble
Observed institutions:
Agence Nationale de Sécurité du Médicament et des Produits de Santé,
Groupe Hospitalier Mutualiste de Grenoble
ORCID:
0000-0001-6485-4951
Observed ORCID:
0000-0001-6485-4951
OpenAlex ID:
A5067436330
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)
2020
·
Astrid Lièvre
, Anthony Turpin
, et al.
·
European Journal of Cancer
·
175
PDF
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
2021
·
Emmanuelle Jacquet
, Ghania Kerouani-Lafaye
, et al.
·
European Journal of Cancer
·
23
PDF
Early access to health products in France: Major advances of the French “Conseil stratégique des industries de santé” (CSIS) to be implemented (modalities, regulations, funding)
2018
·
Nicolas Albin
, Frédéric Chassagnol
, et al.
·
Therapies
·
13
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019
2022
·
Fiona Y.‐V. Pham
, Emmanuelle Jacquet
, et al.
·
International Journal of Cancer
·
11
Access to innovation through the national early access program and clinical trials for patients with malignant melanoma
2021
·
Claire Christen
, Laetitia Belgodère
, et al.
·
Cancer
·
10
PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study
2025
·
Hugo Jourdain
, Nicolas Albin
, et al.
·
The Lancet Regional Health - Europe
·
7
PDF
Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program
2022
·
F.Y.-V. Pham
, E. Jacquet
, et al.
·
Annals of Oncology
·
6
Accès précoce aux produits de santé en France : des avancées majeures du CSIS (Conseil stratégique des industries de santé) à concrétiser (modalités, réglementations, financements)
2018
·
Nicolas Albin
, Frédéric Chassagnol
, et al.
·
Therapies
·
4
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study
2024
·
Hugo Jourdain
, Nicolas Albin
, et al.
·
Clinical and Translational Gastroenterology
·
2
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab
2023
·
Emmanuelle Jacquet
, Fiona Pham
, et al.
·
Cancer Chemotherapy and Pharmacology
·
2
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma
2019
·
Nicolas Albin
, Adrien Monard
, et al.
·
Cancer Chemotherapy and Pharmacology
·
2
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study
2025
·
Jerome Alexandre
, Philippe Boudier
, et al.
·
BMJ Open
·
1
Clinical relevance of reports on early access programs for checkpoint inhibitors in cancer patients: a French retrospective nationwide cohort study
2024
·
A. Chatain
, C. Fenioux
, et al.
·
ESMO Open
·
1
Deux cents ans d’histoire des usages et mésusages du protoxyde d’azote
2024
·
Estelle Cotte Raffour
, Laura Durin
, et al.
·
Annales Médico-psychologiques revue psychiatrique
·
1
Délais administratifs des RTU, effet sur l’accès à l’innovation dans le mélanome
2021
·
Cécile Auger
, Bernard Guillot
, et al.
·
Bulletin du Cancer
·
1
PDF
Evaluation of Clinical Trials in Onco-haematology: A New Method Based on Risk Analysis and Multidisciplinarity
2021
·
J. Lapière
, C. Christen
, et al.
·
Therapeutic Innovation & Regulatory Science
·
1
Étude pilote sur l’intérêt d’une offre systématique de substituts nicotiniques en préopératoire en cas de consommation quotidienne de tabac
2025
·
Estelle Cotte Raffour
, Cécile Viboud
, et al.
·
Revue Francophone Internationale de Recherche Infirmière
[Early access to innovative drugs, ethical impacts].
2022
·
Nicolas Albin
, Emmanuelle Jacquet
, et al.
·
PubMed
Response to the letter: Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
2021
·
Emmanuelle Jacquet
, Adrien Monard
, et al.
·
European Journal of Cancer
La thérapie libre: Expérimenter un nouvel accompagnement du cancer du sein
2021
·
Julia Rautenberg
, Adrien Monard
, et al.
·
Le Journal des psychologues
Access to innovation through the French Expanded-Access Program and clinical trials in patients with malignant melanoma.
2020
·
Claire Christen
, Laetitia Belgodere
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
23
Citation count:
610
H-index:
7
I10-index:
7
Year
Topic
Type